Bill
Look for operative text.
A filed bill, a hearing, and an enacted statute have different legal effects. Confirm the stage, effective date, and stated scope.
Texas + federal record / updated through 2026
Policy Timeline
A careful chronology of policy signals, controlled-substance rules, legislative proposals, and research-access boundaries affecting ibogaine in Texas.
01 / baseline
The federal rule remains the primary constraint.
Ibogaine is listed in Schedule I under the federal Controlled Substances Act. The current federal listing can be checked in the DEA’s Schedule I regulation, which is the starting point for assessing possession, manufacture, distribution, and research controls.
The schedule history matters because it frames later Texas discussion: state interest in research, hearings, or pilot concepts does not by itself remove federal restrictions. For a plain-language map of the subject before applying it to Texas, the site’s ibogaine policy overview separates broad legal context from claims made by individual facilities.
Public discussion often uses “treatment center” as a broad label. That label does not establish that a program is operating under an FDA research authorization, has a required controlled-substance registration, or may lawfully provide ibogaine. The federal Investigational New Drug application framework is the relevant reference point for clinical investigation of an unapproved drug in the United States.
02 / chronological record
Milestones to read in sequence.
Entries identify the policy actor, the practical change, and the boundary that should not be inferred from the record.
-
2000s–present
Federal baseline
U.S. Drug Enforcement Administration / Congress
Ibogaine remains federally controlled as a Schedule I substance. The classification means that a Texas-specific policy proposal cannot, on its own, create ordinary commercial access or replace federal research and registration requirements.
-
2017–2020
Renewed policy attention to psychedelic research
Federal agencies, academic institutions, and state legislatures
Public interest in psychedelic research widened nationally. General background on the compound is available through the ibogaine reference entry, but historical description is not evidence that a Texas provider is authorized to administer it.
-
2023
Texas Senate Bill 2308 enacted
Texas Legislature / Governor of Texas
Senate Bill 2308’s legislative history records a Texas law directing a study of certain psychedelic substances and their potential therapeutic use. The enactment authorized a state study structure; it did not legalize commercial ibogaine treatment or override federal law.
-
2023–2024
Agency and study implementation context
Texas Health and Human Services Commission and designated state participants
The policy significance is procedural: Texas agencies may gather information, contract for study work, and report findings within the statute’s limits. Any claimed operational program still requires separate verification of its research approvals, controlled-substance handling authority, and applicable oversight.
-
2025–2026
Continuing legislative and research discussion
Texas lawmakers, agencies, institutions, and prospective research collaborators
Announcements, hearings, and consortium language can indicate interest or planning. They are not interchangeable with a published protocol, an institutional review board approval, an FDA authorization, or evidence of lawful commercial treatment access.
03 / Texas policy signal
What SB 2308 changed—and what it did not.
SB 2308 created a state-level path for studying certain psychedelic substances, including ibogaine, in a defined policy context. The bill text and its legislative record are the appropriate primary materials for identifying what lawmakers authorized, rather than promotional summaries that may extend beyond the statute.
The enactment did not convert ibogaine into an approved prescription medicine, create a general Texas license for commercial ibogaine centers, or displace federal controlled-substance rules. The Food and Drug Administration’s drug development and approval process remains relevant to claims that imply approved therapeutic availability.
That distinction is central to the site’s research-versus-treatment guide: research-authorized access is bounded by protocol, oversight, participant criteria, and legal permissions; commercial treatment language is a different claim that must be evaluated on its own evidence.
Agency
Look for a published action.
Guidance, contracts, study reports, and notices should be identified by the agency and source document—not by a secondary announcement alone.
Research
Look for oversight evidence.
Institutional review, FDA status, and controlled-substance permissions are distinct questions. One does not prove the others.
04 / verification path
A practical reading order for claims about access.
Use the sequence below to avoid treating a policy announcement as proof of a treatment offering.
Identify the claim
Is the claim about a bill, a study, an FDA process, an agency action, or a commercial service?
Find the primary record
Prioritize official bill pages, agency releases, regulations, court dockets, and institutional notices.
Check the scope
Read for limits: dates, participants, substances, funding, oversight, reporting, and jurisdiction.
Keep categories separate
Do not infer clinical availability from policy interest, research planning, or advertising terminology.
05 / comparison
Policy discussion is not proof of authorized treatment.
Research-authorized activity
- Has a defined protocol and stated oversight structure.
- May involve FDA and controlled-substance requirements that are specific to the research activity.
- Does not establish general public access or ordinary commercial availability.
Commercial treatment claims
- Should not be treated as authorization merely because they use clinical language.
- Require separate scrutiny for legal status, representation, and relevant licensing claims.
- Do not become validated by a Texas hearing, a study proposal, or an out-of-state example.
06 / frequently asked
Questions the timeline can answer.
Does this timeline establish that a Texas facility can provide ibogaine treatment?
No. A policy timeline does not replace verification of federal controlled-substance status, FDA requirements, state licensing rules, or the facts of an individual program. It is a tool for identifying what a cited policy action actually did.
What is the difference between an FDA-authorized study and commercial treatment?
An FDA-authorized study is governed by a research protocol and oversight process. Commercial advertising or treatment language does not itself demonstrate FDA authorization or lawful access. For broader consumer-risk context, ibogaine therapy background can be read alongside primary regulatory records.
Why do Texas bills and hearings matter if federal law applies?
Texas legislative activity can shape state policy priorities, study proposals, funding discussions, and agency attention, but it does not independently change federal scheduling or FDA requirements. The site’s Texas legal considerations page keeps those overlapping layers in view.
Working principle
Treat every policy claim as a source-checking task.
When a claim concerns ibogaine access in Texas, start with the law, regulation, agency record, or documented research authorization it names. Policy interest is meaningful context; it is not a substitute for verified legal and regulatory status.